A recent paper published in the Respiratory Medicine journal investigates the connection between the number and type of bacteria present in the bronchi (the tubes through which air reaches and is spread around the lung) of patients with bronchiectasis and how badly the disease affects them. It was part of the Bronch UK research partnership involving multiple centres across the country, including UCLH. Sputum samples and clinical data—including lung function, blood inflammatory markers, and quality of life measures—were collected when patients had stable controlled bronchiectasis and during exacerbations. The types and quantity of bacteria present in the sputum were measured using advanced techniques based on measuring bacterial DNA.
The key findings were that the numbers of bacteria and the types of bacteria tended to be stable when samples from the same patient were measured repeatedly, and that having an infective exacerbation and antibiotics had limited effects on this. These findings contribute further to our understanding of infection of the bronchi in bronchiectasis and their relationship with clinical outcomes.
In summary, the results provide further support for the concept that, in bronchiectasis, what seems to be relatively minor changes in the bacteria present in the bronchi can cause an exacerbation, and this fits with the recent concept that it is the inflammatory response to these minor changes in bacteria that drives many of the symptoms. However, it remains important to use antibiotics for exacerbations, as it is clear cut that these improve how the patients feel and reduces long term lung damage.
You can read the full article here.
[Posted Jan 2025]